Skip to main content

Table 1 Summary of study characteristics

From: Serum and blood based biomarkers for lung cancer screening: a systematic review

  Jett et al. 2014 Sozzi et al. 2014 Montani et al. 2015
Test Evaluated EarlyCDT-lung MSC miR-test
Number of patients 1613 939 1008
Patient Inclusion Criteria EarlyCDT-lung test made available to treating physicians Clear inclusion criteria not defined MILD trial participants: > 20 pack-years smoking history
> 50 years old without history of cancer in past 5 years.
1000 consecutive plasma samples from trial participants
Additional 69 plasma samples from 85 patients with lung cancer in MILD trial
COSMOS trial participants:
> 20 pack-years smoking
> 50 years old Lung cancer patients diagnosed outside of COSMOS trial
Patient Exclusion Criteria Clear exclusion criteria not defined Hemolyzed samples No known pulmonary pathology No known pulmonary pathology
Follow-up Period 6 months 5 years Unknown
Key Study limitations Audit trial used in regular physician practice
No clear eligibility criteria
No clear lung cancer diagnostic criteria
No baseline characteristics of population
No distribution of alternative diagnosis in those without target condition
No discussion of study limitations, biases, uncertainty
No link to full study protocol
No discussion of sources of funding
No discussion of how sample size was determined
No distribution of alternative diagnosis for those without lung cancer
No indication of whether clinical information available to performers/readers of tests
No discussion of how sample size was determined
No distribution of alternative diagnosis in those not diagnosed with lung cancer
Very brief discussion of study limitations